brentuximab vedotin,nivolumab
bms,pfizer,seagen
['lymphoma', 'cml', 'hodgkin', 'adcetris', 'opdivo', '$pfe', 'seagen', '$sgen']
seagen says adcetris regimen with opdivo leads to 98% response rate in classical hodgkin lymphoma $sgen $pfe #icml23 
The latest global #pharma news, insights, analysis, and views providing you with an information edge.  FirstWord Pharma. Where people who know first, go first.